A clinical diagnostics company and biotech firm have announced a partnership to develop a blood-based tau pathology test that would assist in the diagnosis of Alzheimer’s disease. In a press ...

a leading innovator in clinical diagnostics, today announced a collaboration with Phanes Biotech to co-develop a blood-based Alzheimer’s disease (AD) tau pathology test. Phanes Biotech is an ...

is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an ...

ARUP Laboratories has introduced a blood test for phosphorylated tau 217 (pTau 217) to aid in diagnosing the pathology of Alzheimer's disease in individuals aged 60 years and above experiencing ...

GoPath Diagnostics, a leading provider of molecular and digital pathology services, today announced the launch of DiabetesNow ...

A study from PreciseDx showed that its artificial-intelligence-guided pathology test could help predict a patient’s chances of their breast cancer returning on par with a leading genomic approach.

Leaders most often associate it with measurable benefits: more effective therapies (80%), more accurate diagnoses (75%), and improved patient outcomes (61%). Some also point to increased collaboration ...

Testing recommendations could change if scientists find drugs that can delay or halt Alzheimer’s pathology in people who have not yet developed cognitive problems. But for now, said Dr.

The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the Digital ...

Three large pathology companies, Ampath, PathCare and Lancet Laboratories, yesterday denied before the Competition Tribunal that they had charged excessive prices for COVID-19 PCR tests and ...

Companies in the sector are running a Keep Pathology Bulk-Billed campaign, arguing that the gap between the costs of administering the tests and what companies are paid by the government continues ...

The 2025-26 Budget will deliver a new $492 million NSW Health Pathology Statewide Hub as part of the Minns Labor Government’s plan to improve essential health services for the people of NSW.